跳至主要内容
临床试验/NCT00292409
NCT00292409已完成3 期

A Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices

Otsuka Pharmaceutical Development & Commercialization, Inc.0 个研究点目标入组 400 人开始时间: 2005年3月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
400
主要终点
Clinical Global Impression-Improvement at endpoint

研究概览

简要总结

The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •diagnosis of schizophrenia or schizoaffective disorder being treated as outpatients,no response to past antipsychotic treatment and patients who symptoms are notoptimally controlled defined as CGI- S<7

排除标准

  • •pregnant or breastfeeding,patients at risk for committing suicide,diagnosis of mood disorders, delirium, dementia and other cognitive disorders,patients treatment resistant to otherantipyschotic medications and treatment with a long acting psychotic in which the last dose was within 3 months of treatment phase

结局指标

主要结局

Clinical Global Impression-Improvement at endpoint

次要结局

  • Investigator's Assessment Questionnaire
  • Patient preference of medication at endpoint
  • Clinical Global Impression scale

研究者

相似试验